Abeona Therapeutics (NASDAQ:ABEO) CFO Joseph Walter Vazzano Sells 18,666 Shares

Abeona Therapeutics Inc. (NASDAQ:ABEO) CFO Joseph Walter Vazzano sold 18,666 shares of the company’s stock in a transaction dated Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total value of $99,489.78. Following the completion of the sale, the chief financial officer owned 568,560 shares of the company’s stock, valued at $3,030,424.80. This represents a 3.18% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Abeona Therapeutics Price Performance

Shares of ABEO opened at $5.36 on Friday. The stock has a market cap of $290.46 million, a P/E ratio of 4.36 and a beta of 1.12. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The stock’s 50-day moving average price is $5.07 and its two-hundred day moving average price is $5.64. The company has a current ratio of 9.74, a quick ratio of 9.53 and a debt-to-equity ratio of 0.06.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings results on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, equities analysts predict that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current year.

Institutional Trading of Abeona Therapeutics

A number of institutional investors have recently modified their holdings of ABEO. Adage Capital Partners GP L.L.C. grew its holdings in shares of Abeona Therapeutics by 14.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 3,072,985 shares of the biopharmaceutical company’s stock worth $17,455,000 after buying an additional 381,357 shares in the last quarter. Vanguard Group Inc. boosted its position in Abeona Therapeutics by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,602,901 shares of the biopharmaceutical company’s stock worth $13,743,000 after acquiring an additional 95,878 shares during the last quarter. Boone Capital Management LLC acquired a new position in Abeona Therapeutics during the 2nd quarter worth approximately $7,126,000. Geode Capital Management LLC grew its stake in shares of Abeona Therapeutics by 129.1% during the 2nd quarter. Geode Capital Management LLC now owns 1,105,862 shares of the biopharmaceutical company’s stock worth $6,282,000 after acquiring an additional 623,243 shares in the last quarter. Finally, Kennedy Capital Management LLC raised its holdings in shares of Abeona Therapeutics by 56.4% in the third quarter. Kennedy Capital Management LLC now owns 1,050,863 shares of the biopharmaceutical company’s stock valued at $5,549,000 after purchasing an additional 378,860 shares during the last quarter. 80.56% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on ABEO shares. Weiss Ratings reissued a “sell (d+)” rating on shares of Abeona Therapeutics in a research note on Wednesday. Wall Street Zen lowered Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Abeona Therapeutics in a research note on Monday, October 13th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.